The characteristics of the 513 younger patients including age, AML status (de novo vs. secondary), performance status, WBC count, cytogenetic risk and FLT3-ITD, NPM1, or CEBPA mutations in intermediate-cytogenetic risk were well balanced during the study period (Table 1). This evidence concerns the gene CEBPA and acute myeloid leukemia.